(Q77291934)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

title

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

G Dangas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J J Badimon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

D A Smith

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

A H Unger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

D Levine

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J H Shao

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

P Meraj

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

C Fier

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

J A Ambrose

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

language of work or name

English

0 references

publication date

1 April 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

1294-1304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Angiographic morphology and the pathogenesis of unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effect of atorvastatin on plasma fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Plasma tissue plasminogen activator levels in patients with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Hemostatic function and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Platelet function in hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Increased thromboxane biosynthesis in type IIa hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900018-2

7 January 2021

10.1016/S0735-1097(99)00018-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10193730%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference